Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. [electronic resource]
Producer: 20120330Description: 779-89 p. digitalISSN:- 1538-7445
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Area Under Curve
- Bevacizumab
- Blotting, Western
- Camptothecin -- administration & dosage
- Capecitabine
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cetuximab
- Colorectal Neoplasms -- drug therapy
- Deoxycytidine -- administration & dosage
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- drug effects
- Erlotinib Hydrochloride
- Fluorouracil -- administration & dosage
- HCT116 Cells
- HT29 Cells
- Humans
- Indoles -- administration & dosage
- Irinotecan
- Kaplan-Meier Estimate
- Mice
- Mice, Nude
- Mitogen-Activated Protein Kinases -- metabolism
- Mutation
- Phosphorylation -- drug effects
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Quinazolines -- administration & dosage
- Sulfonamides -- administration & dosage
- Vemurafenib
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.